| INTRODUC TI ON
The emergence of novel therapeutics demonstrating high cure rates from chronic hepatitis C virus (HCV) infection has allowed public health leaders to envision the possibility of its global elimination as a public health threat by year 2030. 1 However, the majority of the estimated 71 million infected worldwide are unaware of their status, which constitutes a major challenge to elimination. 2 The diagnosis of HCV infection is performed by a qualitative or quantitative RNA nucleic acid test (NAT); the latter is commonly referred to as the viral load (VL) test. 3 3.17, 10.69) or 0.69 log 10 IU/mL and reports across a range of 10-100 000 000 (1.0-8.0 log 10 ) IU/mL. 6 Xpert is a more robust platform than conventional platforms and implementable with minimal laboratory set-up. It allows patients to receive their HCV diagnosis within two hours at the price of $17.10 per cartridge, which is the preferential pricing for low-and middle-income countries. Although this is an ex-works price, it is nonetheless lower than conventional platforms which cost $60 to $95 per VL test in commercial laboratories across Cambodia. 7 Moreover, as part of Cepheid's High Burden Developing Countries Program, the purchase of significant volumes of Xpert cartridges further reduces their price. 4 For example, the price can be reduced from However, the implementation of Xpert in Southeast Asia is constrained by the lack of evidence on its field performance where genotype 6 (GT6) predominates. [9] [10] [11] Evidence used to demonstrate clinical performance in the WHO Prequalification Programme relied predominantly on results from GT1 patients, with the inclusion of only 23 non-GT1 samples. 6 Previous studies evaluating the performance of the Xpert assay have also been conducted in resourcerich countries where the majority of the samples tested were GT1/ GT3. 5, 12 Non-GT1/GT3 HCV is prevalent in low-and middle-income countries in East and Southeast Asia, North Africa, the Middle East, and Southern sub-Saharan Africa and is disproportionately underrepresented in the literature. 5, 6, [9] [10] [11] [12] GT6 is one of the most common genotypes in Southeast Asia and is also the most variable with high genetic heterogeneity compared to other genotypes which may affect the reliability of HCV RNA quantification. 13 This underscores the importance of assessing the field performance of Xpert in resource-limited contexts among GT6 patients prior to using the platform in regions with a high prevalence of this genotype.
We aimed to compare the performance of HCV VL testing using
Xpert at a clinic against the Roche HCV VL test performed at a ref-
erence laboratory among a GT6 predominant patient population in Cambodia.
| MATERIAL S AND ME THODS

| Study setting
The study was conducted at the Médecins Sans Frontières' (MSF) (Doctors Without Borders) HCV clinic located in the Preah Kossamak
Hospital in Phnom Penh, Cambodia. One week prior to participant recruitment, a laboratory was set up in a room of the clinic previously used for administrative purposes. The minimal laboratory setup included a water supply, air conditioner, two-four-module Xpert machines with power backup and voltage stabilizers, one desktop computer, two centrifuge machines, one vortex, and one 200-litre fridge to store samples. Prior to study launch, four laboratory technicians received a two-day training provided by Cepheid and an experienced laboratory manager.
| Sample size
We calculated the sample size for the sensitivity and specificity of diagnostic studies using the methods described by Naing et al 14 At an expected sensitivity of 98% and prevalence (proportion of viremic patients among seropositive patients) of 72% based on clinic operational data, the desired sample size for the qualitative assessment was calculated as 263 seropositive patients. Considering that 45% of patients would be GT6 from previous clinic data, the total sample size required to make the same conclusion for GT6 patients was calculated as 585 seropositive patients (=263/0.45). This sample size was also adequate for the Bland-Altman analysis at 80% power and an alpha level of 0.05 using calculation methods presented by Lu et al 15 with an expected mean of differences at μ = 0.03, standard deviation (SD) of differences at σ = 0.2, and a predefined clinical agreement limit for the maximum allowed difference between two methods set at 0.5 log 10 IU/mL from the previous literature. 5 We determined that 585 seropositive patients were adequate to obtain the 156 GT6
patients calculated for the quantitative analysis. patient, 20 mL of venous whole blood was collected in five 4-ml ethylenediaminetetraacetic acid (EDTA) tubes at the same timethree tubes were kept for VL testing using Xpert and for backup in the event that additional blood for retesting was needed, and two tubes were transported to the reference laboratory within 18 hours.
| Clinical samples
Samples were transported to the reference laboratory twice each day in a cooler box kept between 2 and 22°C (one-hour transport).
| Xpert ® (Cepheid) HCV RNA viral load testing at the clinic
The Xpert HCV VL test was performed at MSF's HCV clinic, according to the manufacturer's protocols. 6 We extracted fresh plasma from three EDTA tubes into a homogenized sample and aliquoted them for storage and VL testing. The fresh plasma samples were maintained at 2-8°C and (almost all) tested on the same day as the blood draw using the Xpert platform; on rare occasions, when the number of patients recruited in the study exceeded the laboratory capacity during the week, a few plasma samples were frozen over A phylogenetic tree was constructed according to the maximum likelihood method using the MEGA6 software 18 to determine the HCV genotype.
| Data collection
We prospectively collected data on patient age, sex, previous HCV treatment history, results of transient elastography using . 19 The VL and genotype data were entered in REDCap using printed results obtained from MSF and IPC laboratories. All data were double entered by two independent data entry operators and cleaned for any discrepant entries prior to analysis. The study was approved by the Cambodian National Ethics Committee for Health Research (Reference: 148 NECHR). Samples and data were only collected from patients providing written informed consent for participation in the study.
| Statistical analysis
We used descriptive statistics to report aggregated demographic and baseline characteristics of the patients included in the study. respectively. Twenty-nine (6.4%) samples fell outside of the LOA (16 were GT1b, seven GT6, two GT2a, and four indeterminate genotype). Sixty-three (13.9%) samples fell outside the predefined clinical agreement limit for the maximum allowed difference between two methods which were set at 0.5 log 10 IU/mL. Stratified by GT, the proportion of samples falling outside this ±0.5 log 10 IU/ mL range was 15.5% (n = 31/200) for GT1 and 10.8% (n = 21/195) for GT6. For these 63 samples falling outside the predefined clinical agreement limit, the VL values for Xpert were larger than Roche for 82.5% (n = 52/63) of the samples. Variability in the difference between the two platforms was greater for mean VL values around 4-6 log 10 IU/mL, but smaller for higher VL values of 6.5-7.5 log 10 IU/ mL ( Figure 2B ).
| RE SULTS
In the analyses by genotype (Figure 3 
| D ISCUSS I ON
We showed that in a resource-limited clinical setting, among a patient population with a high prevalence of GT6 HCV infection, the Xpert assay performed well under field conditions compared to the Roche VL conducted in a reference laboratory. In our study, the sensitivity of Xpert compared to Roche was 100% (95% CI 99.2, 100.0). been diagnosed with chronic HCV infection had they used the Roche platform. In the diagnosis of chronic HCV, more research is needed to understand the clinical significance and proper interpretation of VL values close to the lower LOQ.
For the quantitative analysis, we found a small mean difference between the Xpert and Roche assays: −0.01 log 10 IU/mL (95% CI −0.05, 0.02) for all GTs indicating the absence of systematic bias. The mean difference for GT6 was −0.07 log 10 IU/mL (95% CI −0.12, −0.02) and was comparable to the results from GT1 patients. In addition, the LOA was −0.76 to 0.73 for all GTs, with similar results for GT6, for which the LOA was −0.76 to 0.62. Our LOA was greater than the predefined clinical agreement limit for the maximum allowed difference of 0.5 log 10 IU/mL, and 13.9% (=63/454) of samples fell outside this limit. Our LOA was also wider compared to previous studies by: Gupta 5, 12, 20 This may be attributable to differences in sample preparation procedures and the differences in the comparator platforms. Contrary to the three previous studies, we also did not create a homogenous plasma sample before aliquoting the samples designated for testing on the two platforms, although all samples were obtained at the same time from the patients. Venous whole blood samples were centrifuged and prepared to be processed on the PCR assay in their respective laboratories. There was also a greater lag time between blood sampling and VL testing for samples performed at the reference laboratory that may explain why, for the majority (82.5%) of the 63 samples falling outside the predefined clinical agreement limit, the VL values were greater for Xpert compared to Roche. Although HCV RNA is known to be stable even at room temperature, variability in sample storage and handling and lag times to testing, as well as dissimilarities inherent to the platforms, may have contributed to the differences in the RNA quantification of the 63 samples. 21, 22 However, from both the qualitative and quantitative study results, we find no evidence to suggest that the Xpert platform performs differently for GT6 HCV compared to other genotypes. The study supports the use of this platform in clinical settings where GT6
HCV is present.
Our study has some limitations. First, we did not further investigate samples that were outside of the predefined clinical agreement limit by repeating VL testing using other platforms as we did not see Our study findings demonstrate the excellent performance, in terms of sensitivity (100%) and specificity (98.5%), of the Xpert platform compared to the Roche platform and support the use of the Xpert HCV assay in regions where GT6 HCV is prevalent in the patient population.
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